DOI: 10.1055/s-00000020

Geburtshilfe und Frauenheilkunde

References

Loibl S, Marmé F, Martin M. et al.
Phase III study of palbociclib combined with endocrine therapy (ET) in patients with hormone-receptor-positive (HR+), HER2-negative primary breast cancerand with high relapse risk after neoadjuvant chemotherapy (NACT): First results from PENELOPE-B.

Cancer Res 2021;
81 (Suppl. 04) GS1-02
doi:10.1158/1538-7445.SABCS20-GS1-02

Download Bibliographical Data

Search in:
Access: